Federal Circuit Affirms Legality of Skinny Labeling for Generic Pharmaceuticals

The U.S. Court of Appeals for the Federal Circuit recently issued a decision in *Teva Pharmaceuticals USA, Inc. v. GlaxoSmithKline LLC*, affirming the legality of “skinny labeling” practices in the pharmaceutical industry. The ruling confirms that generic drug manufacturers may carve out specific patented indications from their product labels while still marketing the drug for other, non-patented uses. This decision maintains the current regulatory framework that allows generic versions of medications to enter the market even when certain uses of the drug remain under patent protection.

The court’s opinion clarifies the evidentiary standards required to prove that a generic manufacturer induced infringement of a method-of-use patent. The judges determined that a generic company’s “skinny label”—which explicitly excludes the patented indication—does not, by itself, constitute evidence of intent to encourage doctors to prescribe the drug for that protected use. By upholding this practice, the court preserves the ability of generic companies to utilize the FDA’s 505(j) pathway to bring lower-cost alternatives to consumers. The ruling distinguishes between the mere knowledge that a drug might be used for a patented purpose and the active promotion of that use, establishing that generic manufacturers do not face liability simply because a physician chooses to prescribe a drug for an off-label purpose.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 7, 2026

Author

GOAI